New tuberculosis drug leads from naturally occurring compounds

Area of Science:

• Microbiology
• Pharmacology
• Natural Products Chemistry

Background:

• Tuberculosis (TB) causes significant global mortality and morbidity, with 2 billion infected and 10 million new cases annually.
• Existing drugs and vaccines have limited impact on TB control, exacerbated by the rise of multidrug-resistant strains.
• Declining antibiotic development efforts contrast with the urgent need for new anti-TB therapies.

Purpose of the Study:

• To review recent advancements in developing tuberculosis drug leads from natural product sources.
• To highlight anti-mycobacterial compounds derived from nature that are in late-stage preclinical and clinical development.

Main Methods:

• Literature review of scientific publications and clinical trial databases.
• Focus on natural product-derived compounds with demonstrated anti-mycobacterial activity.
• Analysis of compounds in late-stage preclinical and clinical development for tuberculosis.

Main Results:

• Natural products offer rich chemical diversity and inherent antimicrobial properties, making them valuable sources for drug discovery.
• Several natural product-derived compounds show significant promise against Mycobacterium tuberculosis.
• Identification of specific anti-TB drug leads from natural sources progressing through advanced development stages.

Conclusions:

• Natural products represent a vital and underexplored resource for developing new anti-tuberculosis drugs.
• Compounds derived from nature are advancing in development pipelines, offering hope against drug-resistant TB.
• Continued research into natural product-based therapies is crucial for combating the global TB epidemic.